Apo E allele frequencies in Alzheimerʼs disease, Lewy body dementia, Alzheimerʼs disease with cerebrovascular disease and vascular dementia
The DOI matches its Crossref record.
Abstract
Apolipoprotein (Apo E) was genotyped using a fluorescent PCR-RFLP assay in 187 patients with a probable or possible clinical diagnosis of sporadic Alzheimer's disease (AD) and in 166 autopsied patients with dementia (21 presenile AD, 70 senile AD, 18 Lewy body dementia (LBD), 38 AD with cerebrovascular disease (AD-CVD), 19 vascular dementia). The relative epsilon 4 allele frequency was 0.472 in LBD, 0.513 in AD-CVD, 0.405 in presenile AD, 0.364 in senile AD, and 0.079 in vascular dementia. The relative epsilon 2 allele frequency was 0.211 in vascular dementia, 0.083 in LBD, 0.047 in presenile AD, 0.100 in senile AD and 0.039 in AD with CVD. We infer that apo E is a major risk factor for structural phenotypes of dementia involving AD, alone or in conjunction with another pathology. In addition, the epsilon 2 allele is likely to represent a risk factor for vascular morbidity, as the relative epsilon 2 allele frequency was 0.211 in patients with vascular dementia compared with 0.144 in elderly controls.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Apolipoprotein E: an important gene and protein to follow in laboratory medicine
Siest, G., Pillot, T., Régis-Bailly, A., Leininger-Muller, B., Steinmetz, J., Galteau, M. M., & Visvikis, S. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.8.1068 · Cited by 347
Aluminium in Alzheimer?s disease: are we still at a crossroad?
Gupta, V. B., Anitha, S., Hegde, M. L., Zecca, L., Garruto, R. M., Ravid, R., Shankar, S. K., Stein, R., Shanmugavelu, P., & Jagannatha Rao, K. S. (2005) · CMLS Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4317-3 · Cited by 290
Apolipoprotein E epsilon4 and the risk of dementia with stroke. A population-based investigation
Slooter, A. J. C. (1997) · JAMA · doi:10.1001/jama.277.10.818 · Cited by 286
Aluminum Forms in Drinking Water and Risk of Alzheimer's Disease
Gauthier, E., Fortier, I., Courchesne, F., Pepin, P., Mortimer, J., & Gauvreau, D. (2000) · Environmental Research · doi:10.1006/enrs.2000.4101 · Cited by 252
Self-citationCognitive impact of subcortical vascular and Alzheimer’s disease pathology
Chui, H. C., Zarow, C., Mack, W. J., Ellis, W. G., Zheng, L., Jagust, W. J., Mungas, D., Reed, B. R., Kramer, J. H., DeCarli, C. C., et al. (2006) · Annals of Neurology · doi:10.1002/ana.21009 · Cited by 247
“) In the sample as a whole, associations between the three pathology scores (Braak and Braak stage [0–VI], HS score [0– 6], and CVDPS score [0–300]; independent variables) and global cognitive score (0–100; dependent variable) were assessed by multiple linear regression analysis.”
Method
Metadata
- Authors
- Bétard, C., Robitaille, Y., Gee, M., Tiberghien, D., Larrivée, D., Roy, P., Mortimer, J. A., & Gauvreau, D.
- Venue
- NeuroReport
- Published
- 1994-10
- Volume
- 5
- Issue
- 15
- Pages
- 1893-1896
- ISSN
- 0959-4965 (ISSN-L)
- OpenAlex
- W2025169959
- Cited by
- 81
- References
- 0
- FWCI
- 7.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Apo E allele frequencies in Alzheimerʼs disease, Lewy body dementia, Alzheimerʼs disease with cerebrovascular disease and vascular dementia. https://app.cochat.ai/papers/10.1097/00001756-199410000-00013
- The paper
- Bétard, C., Robitaille, Y., Gee, M., Tiberghien, D., Larrivée, D., Roy, P., Mortimer, J. A., & Gauvreau, D. (1994). Apo E allele frequencies in Alzheimerʼs disease, Lewy body dementia, Alzheimerʼs disease with cerebrovascular disease and vascular dementia. NeuroReport. https://doi.org/10.1097/00001756-199410000-00013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.